27 June 2017
An important debate at this year’s IUGA congress, titled “Blinded by or Seeing the Light – Laser is the Best Treatment for Vaginal Atrophy” introduced Fotona’s breakthrough minimally invasive laser treatment as a direct competitor to the traditional gold standard therapy for genitourinary syndrome of menopause.
While it is not surprising that the GSM therapy was declared the official winner of the session, it is clear from this high-profile debate (the first direct comparison of its kind at a major congress) that an increasing number of practitioners now consider laser treatment to be a very good option for treating GSM. Over the past 8 years we have observed an evolution starting from a total lack of awareness about laser treatment to fierce opposition and eventually to gradual acceptance and now even to direct comparison with the industry’s gold standard.
Dr. Adrian Gaspar did an excellent job in presenting the case for Fotona’s RenovaLase® treatment, which is a unique and innovative, non-invasive 2940 nm Er:YAG laser therapy for the symptoms of vaginal atrophy. It is based on non-ablative photothermal treatment of the vaginal canal to stimulate angiogenesis, fibroblast activity and new collagen formation. Clinical studies show that it is an efficient, easy-to-use, quick and safe procedure that eliminates the need for long-term estrogen administration.
